Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04913285 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment reopened Study sites: 50 to 48v32 Show 1 more changeShow less
    • Study sites: 50 to 48
  2. Re-verified, no change to tracked fieldsv31
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 36 to 50v30 Show 1 more changeShow less
    • Study sites: 36 to 50
  4. Study sites: 29 to 36v29
  5. Primary completion date: Jan 31, 2027 to Nov 30, 2028 Study sites: 28 to 29 · Completion date: May 31, 2027 to Mar 30, 2029v28 Show 2 more changesShow less
    • Study sites: 28 to 29
    • Completion date: May 31, 2027 to Mar 30, 2029
Show 26 earlier versionsHide 26 earlier versions
  1. Primary completion date: Dec 7, 2024 to Jan 31, 2027 Study sites: 43 to 28 · Completion date: Dec 2025 to May 31, 2027v27 Show 2 more changesShow less
    • Study sites: 43 to 28
    • Completion date: Dec 2025 to May 31, 2027
  2. Re-verified, no change to tracked fieldsv26
  3. Lead sponsor: Kinnate Biopharma to Pierre Fabre Medicament Primary completion date: Mar 2024 to Dec 7, 2024 · Completion date: Jun 2024 to Dec 2025v25 Show 2 more changesShow less
    • Primary completion date: Mar 2024 to Dec 7, 2024
    • Completion date: Jun 2024 to Dec 2025
  4. Site details revised at 5 of 43 sitesv24
  5. Enrollment target: 262 to 400 Study sites: 50 to 43 · Secondary endpoints revised (9) · Study arms: 3 to 4v23 Show 3 more changesShow less
    • Study sites: 50 to 43
    • Secondary endpoints revised (9)
    • Study arms: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites: 41 to 50v22
  7. Enrollment target: 155 to 262 Study sites: 38 to 41 · Eligibility criteria shortened, about 13 words · Study description expanded, about 1 wordv21 Show 3 more changesShow less
    • Study sites: 38 to 41
    • Eligibility criteria shortened, about 13 words
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  8. Study sites: 37 to 38v20
  9. Study sites: 34 to 37v19
  10. Site contacts updated at 1 of 34 sitesv18
  11. Study sites: 29 to 34v17
  12. Study sites: 24 to 29 Eligibility criteria expanded, about 35 wordsv16 Show 1 more changeShow less
    • Eligibility criteria expanded, about 35 words

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites: 21 to 24v15
  14. Study sites: 18 to 21v14
  15. Study sites: 15 to 18v13
  16. Study sites: 11 to 15v12
  17. Study sites: 10 to 11v11
  18. Study sites: 7 to 10v10
  19. Re-verified, no change to tracked fieldsv9
  20. Study sites: 6 to 7v8
  21. Study sites: 5 to 6v7
  22. Primary endpoints: 5 to 6 Enrollment target: 115 to 155 · Interventions: KIN-2787 (Drug) to KIN-2787 (Drug), KIN-2787 and binimetinib (Drug) · Eligibility criteria shortened, about 10 words · 4 morev6 Show 7 more changesShow less
    • Enrollment target: 115 to 155
    • Interventions: KIN-2787 (Drug) to KIN-2787 (Drug), KIN-2787 and binimetinib (Drug)
    • Eligibility criteria shortened, about 10 words
    • Secondary endpoints: 3 to 9
    • Study description expanded, about 10 words
    • Study arms: 2 to 3
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  23. Study sites: 4 to 5v5
  24. Study sites: 3 to 4v4
  25. Study sites: 1 to 3 Start date changed from estimate of Jun 2021 to Aug 4, 2021v3 Show 1 more changeShow less
    • Start date changed from estimate of Jun 2021 to Aug 4, 2021
  26. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Trial Details
NCT Number NCT04913285
Lead Sponsor Pierre Fabre Medicament
Conditions Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov